Biotech company Hemostemix: A potential winner of the longevity trend?

Researchers in the cleanroom (Copyright: Depositphotos)

The stock of the Canadian biotech company Hemostemix Inc. (TSXV:HEM, FSE:2VF0) has been tradable on the regulated US OTCQB exchange under the symbol HMTXF since January 23, 2025. Until then, Hemostemix only had a simple OTC listing. The company expects the new listing to improve tradability and increase trading volumes. Also on January 23, 2025, the company presented at the Sequire Investor Summit in Puerto Rico with the presentation "Welcome to Your Fountain of Youth".

Hemostemix CEO Thomas Smeenk commented: "Listing on the OTCQB allows US investors to directly participate in their 'Fountain of Youth' and longevity. As management and directors, we have invested $9.1 million USD in 'Your Fountain of Youth' from Hemostemix since 2020. We have done this because our therapy works. Our treatment with autologous stem cells has proven to be clinically relevant, statistically significant, and safe in 498 treatments and seven clinical studies with 318 subjects."